In FY 2018, the US generic industry faced a tough deflationary period due to customer consolidation and the acceleration of approvals through the US Food and Drug Administration (FDA). These changing market dynamics have affected the whole generic industry due to which many of the company’s peers have reported weaker results, restructured their operations and divested assets.
In FY 2018, Mayne Pharma Group Limited (ASX: MYX)’s revenue decreased by 7 percent to $530.3 million compared to the previous year. The company reported a net loss after tax of $134 million in FY 2018 compared to the last year profit of $88.6 million. These full-year results were impacted by a number of items which includes non-cash intangible asset impairment, extraordinary stock obsolescence, abnormal Doryx returns, a restructuring charge to reduce the cost base and a charge to income tax expense resulting from the US corporate federal tax rate change. There was a significant increase in the operating expenses of the company which was mainly due to the increase of market and distribution expenses to expand specialty brand sales team in the US. The administration expenses also increased due to an increase in the wages and salaries, insurance and rent. At the end of FY 2018, the company was having a cash of $87 million and outstanding borrowings of $374 million. The basic and diluted loss per share is 9.16 cents per share in FY 2018. The company holds positive net cash flow from operating activities of $137 million in FY 2018. [optin-monster-shortcode id=”swikrbu1d9j9aq0o4cko”]
In the second half of FY 2018, the generic products performed strongly driven by the new product launches, normalized levels of stock obsolescence, portfolio optimization and cost savings from the transfer in of Teva acquired products. The Company has also invested more than $150 million over the last three years to transform its manufacturing facilities to bring new capacity and capability on line and support the mid to long-term growth. The company is having R&D capitalization rate of 73 percent in FY 2018. This rate is expected to decline in the upcoming years as the company is planning to invest more in research and development of specialty products and early-stage clinical development programs. The Company is expecting a new sales team in place during Calendar Year 2019.
In the last three months, the share price of the company increased by 31.46 percent as on 12 October 2018. MYX’s share traded at $1.155 with a market capitalization of $1.84 billion as on 15 October 2018 (AEST 4:00 PM).
The Income available from dividends remains attractive for many investors.
We take a look at the best yields on the market and assess what they say about a company’s prospect.
One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”
ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.
Click here to get your free report.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.